INTRODUCTION
Breast cancer is segmented into molecular subgroups defined by genomic alterations involved in tumor progression which could identify patient populations best treated with targeted agents. One such population may be patients with gene alterations in the fibroblast growth factor (FGF) pathway, which consists of 18 different FGF ligands that act on 4 transmembrane tyrosine kinase FGF receptors (FGFR 1-4) (1).
Multiple genetic alterations in FGFRs have been identified in breast cancer.
For example, amplification of FGFR1 (8p11-12) is present in 8% to 15% of all breast cancer (2-4) and 16% to 27% of luminal type B breast cancer (5) . These amplifications correlate with FGFR1 overexpression and are associated with resistance to endocrine therapy and poor prognosis (3, 5) . Preclinical studies suggest that targeting FGFR1 could lead to antitumor effects by decreasing cell viability and restoring endocrine therapy sensitivity. Several other genomic alterations of the FGF pathway have also been observed in breast cancer (6, 7) , including FGFR2 and FGF3/4/19 amplification. 50 values against FGFR1-3, VEGFR1-3, and platelet-derived growth factor receptor (PDGFR) of approximately 10 nM (8, 9) . Phase I studies have suggested that dovitinib has a tolerable safety profile and effectively targets FGFR at therapeutic doses. In order to determine whether FGFR inhibition could lead to antitumor effects in patients with breast tumors harboring FGFR amplifications, we first evaluated the preclinical activity of dovitinib in breast cancer preclinical models, then conducted a phase II trial of dovitinib in patients with metastatic breast cancer, with and without FGFR1-amplification. Importantly, this is the first report of a study selecting patients according to FGFR1-amplification status.
Dovitinib (TKI258) is an oral tyrosine kinase inhibitor (TKI) with in vitro IC

MATERIALS AND METHODS
Preclinical Studies
Effects of dovitinib on cell proliferation using methylene blue staining were assessed after a 72-hour exposure in 13 breast cancer cell lines, including two with FGFR2 copies by qPCR was predefined based on the previous report of Turner, et al
Study Design and Treatment
. Table 1 ). Of note, there were very few cases of FGFR1-amplified HR -disease (n = 2), confirming there is a very low incidence of FGFR1 amplification in patients with triple-negative breast cancer, and this arm was stopped prior to completion of enrollment. 
RESULTS
Dovitinib Had Antitumor Activity in FGFR-Amplified Breast Cancer Models
Dovitinib Effectively Increases FGF23 Plasma Levels, Indicative of FGFR1 Inhibition
FGF23 has been identified as a target gene of FGF signaling in vitro (15).
Furthermore, increases in FGF23 have previously been reported as a surrogate for FGFR1 inhibition in clinical trials of dovitinib in renal cell carcinoma and melanoma (11, 16, 17) . In these trials, 50% to 100% increases of plasma FGF23 from baseline were detected at cycle 1, day 15 and were correlated with reduced pERK (17) . In the data presented here, plasma FGF23 levels peaked ≈ 100% above baseline at cycle 1, day 8 and were sustained over time, suggesting that dovitinib effectively inhibited suggesting that there were no major differences in pharmacodynamic activity between the 3 groups. 
Dovitinib Exhibits Greater Antitumor Effects in FGFR1-Amplified as Compared to Nonamplified Breast Cancers
We further explored whether higher levels of FGFR1 amplification detected by qPCR are predictive for dovitinib sensitivity in patients with HR + disease. Tissue for qPCR assessment was available for 42 of 51 HR + patients with measurable disease.
Thirty-eight of these patients had assessable disease, and in 35 of them the reported change in tumor size was in accordance with the overall tumor response; these are included in this analysis. Thirteen and 22 of these patients were FGFR1 amplified and nonamplified by SISH, respectively. Using qPCR, with a cutoff of 6 copies for 
Safety
All patients eventually discontinued the study, with disease progression as the most common reason reported for discontinuation (n = 47, 58.0%). AEs regardless of relationship to dovitinib were reported as the primary reason for discontinuation in 22 patients (27.2%). AEs leading to discontinuation were most commonly grade 3, the most common being asthenia/fatigue (n = 7), gastrointestinal disorders (n = 5), and investigations of laboratory abnormalities (n = 6, mainly liver function test abnormalities).
All patients (100.0%) experienced at least 1 AE regardless of relationship to study drug, most commonly vomiting (77.8%), diarrhea (76.5%), asthenia (67.9%), and nausea (67.9%) ( Table 3) . Sixty-three patients (77.8%) experienced a grade 3/4 AE. The most common grade 3/4 AEs regardless of study drug relationship were asthenia (23.5%), ALT increase (11.1%), diarrhea (8.6%), and vomiting, fatigue, and AST increase (7.4% each) . No notable differences across the groups were observed (data not shown). Eight patients died on the study or during the 28-day follow-up period. In 3 cases, the fatal event was assessed by the investigator as being related to the study drug, and in the remaining 5 cases, the death was deemed as secondary to 
DISCUSSION
We examined the activity of dovitinib in preclinical models and patients with breast cancer. Our findings suggest that dovitinib could have modest antitumor activity in FGF-pathway amplified tumors, but not in FGF-pathway non-amplified tumors. These data suggest that future trials testing FGFR inhibitors should focus on FGF-pathway-amplified breast cancer.
This study was conducted in a population who was unlikely to respond. These patients had advanced disease (70% had ≥3 organs involved and 78% had liver metastases) and were heavily pretreated, with most having received more than 1 line was not the only genomic alteration identified within the FGF pathway. In our study, FGFR2 amplifications were also associated with a higher number of responders.
Indeed, tumor reductions of 28.2% and 18.5% were observed in 2 evaluable patients with FGFR2 amplification, suggesting that dovitinib could have antitumor activity in this small subset of patients. FGF3 amplification was also associated with tumor shrinkage, with 2 of the 4 FGF3-amplified patients achieving an unconfirmed partial response. Whether FGF3 is a biomarker by itself or a surrogate of high-level FGFR1 amplification is unclear since amplification of the 11q12 amplicon is more likely to occur when FGFR1 is amplified (6) . In the present study, 3 of 4 patients with FGF3 amplification also had a high level of FGFR1 amplification and the fourth patient had a FGFR1-gene gain by qPCR (3.4 copies) . Also, the precise role of FGF3 in the amplicon and oncogenesis is unclear. Indeed, several other candidate oncogenic 
drivers are present on the amplicon including CCND1 and PAK1. Overall, the present study could not address whether FGF3 amplification by itself contributed to the definition of dovitinib-sensitive patients. Another limitation was that the study was not sufficiently powered for statistical analyses on FGF-pathway-amplified vs nonamplified patients.
Further studies of dovitinib will be in combination with endocrine therapy, as targeted therapies present optimal efficacy when combined with other agents. In a similar fashion as the synergy that was observed with everolimus and aromatase inhibitors (21, 22) , FGFR1 inhibition has been shown to reverse endocrine resistance in preclinical models (5) . Since the present study did not address the role of sensitization to endocrine therapy, future combination trials should include both FGFpathway amplified and non-amplified patients. Finally, additional molecular analyses will determine whether FGFR-amplifications could be associated with additional mutations on oncogenes. This biomarker work could provide some rationale for combining dovitinib with other targeted agents with the aim of delaying resistance.
The safety profile of dovitinib includes gastrointestinal toxicity (nausea, vomiting), liver toxicity, and asthenia. This profile is comparable with TKIs (e.g., pazopanib, sunitinib, and lapatinib) but higher than monoclonal antibodies (23) (24) (25) .
Increasing awareness of these effects amongst physicians should accelerate detection and reduce severity of these events.
Overall, the present study provides the first detailed report examining FGFR- 
